BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pancreatic Ductal Adenocarcinoma readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Pancreatic Ductal Ade
 nocarcinoma\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04115163-7671@assetmemo.bio
DTSTAMP:20261121T010011Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT04115163)
DESCRIPTION:Gemcitabine\, phase 2\, Pancreatic Ductal Adenocarcinoma.\nStud
 y: Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclita
 xel for the Treatment of Metastatic Pancreatic Cancer\nEstimated primary c
 ompletion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/gemcitabine#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT04115163
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06492915-7671@assetmemo.bio
DTSTAMP:20261121T010011Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT06492915)
DESCRIPTION:Gemcitabine\, phase 2\, Pancreatic Ductal Adenocarcinoma.\nStud
 y: Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic D
 uctal Adenocarcinoma\nEstimated primary completion: 28 February 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/gemcitabine#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06492915
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06048484-2695@assetmemo.bio
DTSTAMP:20261121T010011Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Quemliclustat: Phase 2 readout est. (NCT06048484)
DESCRIPTION:Quemliclustat\, phase 2\, Pancreatic Ductal Adenocarcinoma.\nSt
 udy: Combination Therapy in Patients With Localized Pancreatic Ductal Aden
 ocarcinoma\nEstimated primary completion: April 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/quemliclustat#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06048484
URL:https://assetmemo.bio/drug/quemliclustat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05379985-2216@assetmemo.bio
DTSTAMP:20261121T010011Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Rasonque (Daraxonrasib): Phase 1/2 readout est. (NCT05379985)
DESCRIPTION:Rasonque (Daraxonrasib)\, phase 1/2\, Non-Small Cell Lung Cance
 r.\nStudy: Study of RMC-6236 in Patients With Advanced Solid Tumors Harbor
 ing Specific Mutations in RAS\nEstimated primary completion: 31 May 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/daraxonrasib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05379985
URL:https://assetmemo.bio/drug/daraxonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05585320-7671@assetmemo.bio
DTSTAMP:20261121T010011Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Gemcitabine: Phase 1/2 readout est. (NCT05585320)
DESCRIPTION:Gemcitabine\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
  Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic
  Solid Tumors\nEstimated primary completion: June 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/gemcitabine#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05585320
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06922591-2073@assetmemo.bio
DTSTAMP:20261121T010011Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Vopimetostat: Phase 1/2 readout est. (NCT06922591)
DESCRIPTION:Vopimetostat\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 Study to Evaluate the Safety\, Tolerability & Efficacy of TNG462 in Combin
 ation in PDAC & NSCLC Patients\nEstimated primary completion: June 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/vopimetostat#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06922591
URL:https://assetmemo.bio/drug/vopimetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06922591-2216@assetmemo.bio
DTSTAMP:20261121T010011Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Rasonque (Daraxonrasib): Phase 1/2 readout est. (NCT06922591)
DESCRIPTION:Rasonque (Daraxonrasib)\, phase 1/2\, Non-Small Cell Lung Cance
 r.\nStudy: Study to Evaluate the Safety\, Tolerability & Efficacy of TNG46
 2 in Combination in PDAC & NSCLC Patients\nEstimated primary completion: J
 une 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/daraxonrasi
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 922591
URL:https://assetmemo.bio/drug/daraxonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07644559-2279@assetmemo.bio
DTSTAMP:20261121T010011Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:GFH375: Phase 2 readout est. (NCT07644559)
DESCRIPTION:GFH375\, phase 2\, Pancreatic Ductal Adenocarcinoma.\nStudy: A 
 Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Can
 cer\nEstimated primary completion: June 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/gfh375#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07644559
URL:https://assetmemo.bio/drug/gfh375#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05825066-7671@assetmemo.bio
DTSTAMP:20261121T010011Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT05825066)
DESCRIPTION:Gemcitabine\, phase 2\, Pancreatic Ductal Adenocarcinoma.\nStud
 y: Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced
  Pancreatic Adenocarcinoma\nEstimated primary completion: June 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/gemcitabine#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05825066
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07163273-7671@assetmemo.bio
DTSTAMP:20261121T010011Z
DTSTART;VALUE=DATE:20270620
DTEND;VALUE=DATE:20270621
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT07163273)
DESCRIPTION:Gemcitabine\, phase 2\, Pancreatic Ductal Adenocarcinoma.\nStud
 y: Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Met
 astatic Pancreatic Ductal Adenocarcinoma\nEstimated primary completion: 20
  June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gemcitabi
 ne#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7163273
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06423326-7671@assetmemo.bio
DTSTAMP:20261121T010011Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT06423326)
DESCRIPTION:Gemcitabine\, phase 2\, Pancreatic Ductal Adenocarcinoma.\nStud
 y: Gemcitabine\, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for
  Patients With Resectable or Borderline Resectable Pancreatic Cancer\nEsti
 mated primary completion: 31 August 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/gemcitabine#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06423326
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07483983-2183@assetmemo.bio
DTSTAMP:20261121T010011Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Setidegrasib: Phase 2 readout est. (NCT07483983)
DESCRIPTION:Setidegrasib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: St
 udy Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non
 -small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC
 )\, With Biomarker Analysis to Characterize Response/Resistance\nEstimated
  primary completion: September 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/setidegrasib#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07483983
URL:https://assetmemo.bio/drug/setidegrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06115499-7671@assetmemo.bio
DTSTAMP:20261121T010011Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Gemcitabine: Phase 2/3 readout est. (NCT06115499)
DESCRIPTION:Gemcitabine\, phase 2/3\, Pancreatic Ductal Adenocarcinoma.\nSt
 udy: The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treat
 ment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cance
 r\nEstimated primary completion: 1 December 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/gemcitabine#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06115499
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05688215-2695@assetmemo.bio
DTSTAMP:20261121T010011Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Quemliclustat: Phase 1/2 readout est. (NCT05688215)
DESCRIPTION:Quemliclustat\, phase 1/2\, Pancreatic Ductal Adenocarcinoma.\n
 Study: Zimberelimab and Quemliclustat in Combination With Chemotherapy for
  the Treatment of Patients With Borderline Resectable and Locally Advanced
  Pancreatic Adenocarcinoma\nEstimated primary completion: 31 December 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/quemliclustat#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05688215
URL:https://assetmemo.bio/drug/quemliclustat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07491445-2216@assetmemo.bio
DTSTAMP:20261121T010011Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Rasonque (Daraxonrasib): Phase 3 readout est. (NCT07491445)
DESCRIPTION:Rasonque (Daraxonrasib)\, phase 3\, Pancreatic Ductal Adenocarc
 inoma.\nStudy: Study of Daraxonrasib and Daraxonrasib + GnP as First-line 
 Treatment in Patients With Metastatic Pancreatic Adenocarcinoma\nEstimated
  primary completion: April 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/daraxonrasib#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07491445
URL:https://assetmemo.bio/drug/daraxonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07076212-7671@assetmemo.bio
DTSTAMP:20261121T010011Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT07076212)
DESCRIPTION:Gemcitabine\, phase 2\, Pancreatic Ductal Adenocarcinoma.\nStud
 y: Evaluating NALIRIFOX vs Modified Gemcitabine\, Nab-Paclitaxel and Cispl
 atin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarc
 inoma\nEstimated primary completion: May 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/gemcitabine#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07076212
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07522073-2548@assetmemo.bio
DTSTAMP:20261121T010011Z
DTSTART;VALUE=DATE:20280915
DTEND;VALUE=DATE:20280916
SUMMARY:INCB161734: Phase 3 readout est. (NCT07522073)
DESCRIPTION:INCB161734\, phase 3\, Pancreatic Ductal Adenocarcinoma.\nStudy
 : A Study to Evaluate Chemotherapy With or Without INCB161734 in Previousl
 y Untreated\, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinom
 a\nEstimated primary completion: 15 September 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/incb161734#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07522073
URL:https://assetmemo.bio/drug/incb161734#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06445062-2216@assetmemo.bio
DTSTAMP:20261121T010011Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Rasonque (Daraxonrasib): Phase 1/2 readout est. (NCT06445062)
DESCRIPTION:Rasonque (Daraxonrasib)\, phase 1/2\, Pancreatic Ductal Adenoca
 rcinoma.\nStudy: Study of RAS(ON) Inhibitors in Patients With Gastrointest
 inal Solid Tumors\nEstimated primary completion: 30 September 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/daraxonrasib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06445062
URL:https://assetmemo.bio/drug/daraxonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06128551-2216@assetmemo.bio
DTSTAMP:20261121T010011Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Rasonque (Daraxonrasib): Phase 1/2 readout est. (NCT06128551)
DESCRIPTION:Rasonque (Daraxonrasib)\, phase 1/2\, Non-Small Cell Lung Cance
 r.\nStudy: Study of Elironrasib and Daraxonrasib as Monotherapies and Comb
 ination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumor
 s\nEstimated primary completion: December 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/daraxonrasib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06128551
URL:https://assetmemo.bio/drug/daraxonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07020221-2279@assetmemo.bio
DTSTAMP:20261121T010011Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:GFH375: Phase 1/2 readout est. (NCT07020221)
DESCRIPTION:GFH375\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Phas
 e 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors\nEs
 timated primary completion: December 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/gfh375#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07020221
URL:https://assetmemo.bio/drug/gfh375#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07803783-2817@assetmemo.bio
DTSTAMP:20261121T010011Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Tambotatug pelitecan: Phase 3 readout est. (NCT07803783)
DESCRIPTION:Tambotatug pelitecan\, phase 3\, Pancreatic Ductal Adenocarcino
 ma.\nStudy: A Study to Compare the Efficacy and Safety of YL201 With Stand
 ard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failu
 re of Gemcitabine-Based Systemic Chemotherapy\nEstimated primary completio
 n: January 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tamb
 otatug-pelitecan#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07803783
URL:https://assetmemo.bio/drug/tambotatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06897644-7671@assetmemo.bio
DTSTAMP:20261121T010011Z
DTSTART;VALUE=DATE:20290101
DTEND;VALUE=DATE:20290102
SUMMARY:Gemcitabine: Phase 3 readout est. (NCT06897644)
DESCRIPTION:Gemcitabine\, phase 3\, Pancreatic Ductal Adenocarcinoma.\nStud
 y: Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuati
 on of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanc
 ed Pancreatic Cancer.\nEstimated primary completion: 1 January 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/gemcitabine#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06897644
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07450859-2421@assetmemo.bio
DTSTAMP:20261121T010011Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Nuzefatide pevedotin: Phase 2 readout est. (NCT07450859)
DESCRIPTION:Nuzefatide pevedotin\, phase 2\, Pancreatic Ductal Adenocarcino
 ma.\nStudy: A Study of Nuzefatide Pevedotin (BT5528) in Patients With Meta
 static Pancreatic Ductal Adenocarcinoma (PDAC)\nEstimated primary completi
 on: March 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nuzef
 atide-pevedotin#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07450859
URL:https://assetmemo.bio/drug/nuzefatide-pevedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07805954-2216@assetmemo.bio
DTSTAMP:20261121T010011Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Rasonque (Daraxonrasib): Phase 3 readout est. (NCT07805954)
DESCRIPTION:Rasonque (Daraxonrasib)\, phase 3\, Pancreatic Ductal Adenocarc
 inoma.\nStudy: Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236
 ) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metasta
 tic KRAS G12D-Mutated Pancreatic Adenocarcinoma\nEstimated primary complet
 ion: March 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dara
 xonrasib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07805954
URL:https://assetmemo.bio/drug/daraxonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07616362-7671@assetmemo.bio
DTSTAMP:20261121T010011Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT07616362)
DESCRIPTION:Gemcitabine\, phase 2\, Pancreatic Ductal Adenocarcinoma.\nStud
 y: Personalize (Signature Driven) Neoadjuvant Chemotherapy Trial for Patie
 nts With Resectable Borderline Pancreatic Ductal Adenocarcinoma.\nEstimate
 d primary completion: April 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/gemcitabine#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07616362
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07076121-2283@assetmemo.bio
DTSTAMP:20261121T010011Z
DTSTART;VALUE=DATE:20290503
DTEND;VALUE=DATE:20290504
SUMMARY:Navlimetostat: Phase 2/3 readout est. (NCT07076121)
DESCRIPTION:Navlimetostat\, phase 2/3\, Pancreatic Ductal Adenocarcinoma.\n
 Study: A Study Comparing Navlimetostat (BMS-986504) in Combination With Na
 b-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclit
 axel and Gemcitabine in Participants With Untreated Metastatic Pancreatic 
 Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)\nEsti
 mated primary completion: 3 May 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/navlimetostat#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07076121
URL:https://assetmemo.bio/drug/navlimetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07252232-2216@assetmemo.bio
DTSTAMP:20261121T010011Z
DTSTART;VALUE=DATE:20290510
DTEND;VALUE=DATE:20290511
SUMMARY:Rasonque (Daraxonrasib): Phase 3 readout est. (NCT07252232)
DESCRIPTION:Rasonque (Daraxonrasib)\, phase 3\, Pancreatic Ductal Adenocarc
 inoma.\nStudy: Study of Daraxonrasib (RMC-6236) in Patients With Resected 
 Pancreatic Ductal Adenocarcinoma (PDAC)\nEstimated primary completion: 10 
 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/daraxonrasi
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 252232
URL:https://assetmemo.bio/drug/daraxonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07905131-2283@assetmemo.bio
DTSTAMP:20261121T010011Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Navlimetostat: Phase 1/2 readout est. (NCT07905131)
DESCRIPTION:Navlimetostat\, phase 1/2\, Pancreatic Ductal Adenocarcinoma.\n
 Study: A Study of Perioperative Navlimetostat Combined With Modified FOLFI
 RINOX in Patients With MTAP-Deleted Pancreatic Cancer\nEstimated primary c
 ompletion: 30 June 2029. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/navlimetostat#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07905131
URL:https://assetmemo.bio/drug/navlimetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07409272-2183@assetmemo.bio
DTSTAMP:20261121T010011Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Setidegrasib: Phase 3 readout est. (NCT07409272)
DESCRIPTION:Setidegrasib\, phase 3\, Pancreatic Ductal Adenocarcinoma.\nStu
 dy: A Study to Evaluate the Effectiveness and Safety of Setidegrasib\, Giv
 en With Either mFOLFIRINOX or NALIRIFOX Chemotherapies\, in People With Pa
 ncreatic Cancer\nEstimated primary completion: 31 August 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/setidegrasib#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07409272
URL:https://assetmemo.bio/drug/setidegrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07748611-7671@assetmemo.bio
DTSTAMP:20261121T010011Z
DTSTART;VALUE=DATE:20300203
DTEND;VALUE=DATE:20300204
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT07748611)
DESCRIPTION:Gemcitabine\, phase 2\, Pancreatic Ductal Adenocarcinoma.\nStud
 y: SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and 
 Borderline Resectable Pancreatic Ductal Adenocarcinoma\, SMART-PANC Trial\
 nEstimated primary completion: 3 February 2030. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/gemcitabine#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07748611
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07096362-7671@assetmemo.bio
DTSTAMP:20261121T010011Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT07096362)
DESCRIPTION:Gemcitabine\, phase 2\, Pancreatic Ductal Adenocarcinoma.\nStud
 y: Utility of ctDNA in Early Switch of First-line Chemotherapy in Metastat
 ic Pancreatic Ductal Adenocarcinoma\nEstimated primary completion: 30 Sept
 ember 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gemcitabi
 ne#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7096362
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06608927-2695@assetmemo.bio
DTSTAMP:20261121T010011Z
DTSTART;VALUE=DATE:20301130
DTEND;VALUE=DATE:20301201
SUMMARY:Quemliclustat: Phase 3 readout est. (NCT06608927)
DESCRIPTION:Quemliclustat\, phase 3\, Pancreatic Ductal Adenocarcinoma.\nSt
 udy: Study of Quemliclustat and Chemotherapy Versus Placebo and Chemothera
 py in Patients With Metastatic Pancreatic Ductal Adenocarcinoma\nEstimated
  primary completion: 30 November 2030. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/quemliclustat#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06608927
URL:https://assetmemo.bio/drug/quemliclustat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05968326-11325@assetmemo.bio
DTSTAMP:20261121T010011Z
DTSTART;VALUE=DATE:20310101
DTEND;VALUE=DATE:20310102
SUMMARY:Autogene cevumeran: Phase 2 readout est. (NCT05968326)
DESCRIPTION:Autogene cevumeran\, phase 2\, Pancreatic Ductal Adenocarcinoma
 .\nStudy: A Study of the Efficacy and Safety of Adjuvant Autogene Cevumera
 n Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participan
 ts With Resected PDAC\nEstimated primary completion: 1 January 2031. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/autogene-cevumeran#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05968326
URL:https://assetmemo.bio/drug/autogene-cevumeran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07897734-2073@assetmemo.bio
DTSTAMP:20261121T010011Z
DTSTART;VALUE=DATE:20311130
DTEND;VALUE=DATE:20311201
SUMMARY:Vopimetostat: Phase 1/2 readout est. (NCT07897734)
DESCRIPTION:Vopimetostat\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 TNG462-C103: Study to Evaluate the Safety\, Tolerability\, and Antitumor A
 ctivity of Vopimetostat in Combination With ERAS-0015 in PDAC and NSCLC Pa
 tients\nEstimated primary completion: November 2031. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/vopimetostat#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07897734
URL:https://assetmemo.bio/drug/vopimetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07897734-2476@assetmemo.bio
DTSTAMP:20261121T010011Z
DTSTART;VALUE=DATE:20311130
DTEND;VALUE=DATE:20311201
SUMMARY:ERAS-0015: Phase 1/2 readout est. (NCT07897734)
DESCRIPTION:ERAS-0015\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: TNG
 462-C103: Study to Evaluate the Safety\, Tolerability\, and Antitumor Acti
 vity of Vopimetostat in Combination With ERAS-0015 in PDAC and NSCLC Patie
 nts\nEstimated primary completion: November 2031. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/eras-0015#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07897734
URL:https://assetmemo.bio/drug/eras-0015#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06714604-7671@assetmemo.bio
DTSTAMP:20261121T010011Z
DTSTART;VALUE=DATE:20321231
DTEND;VALUE=DATE:20330101
SUMMARY:Gemcitabine: Phase 3 readout est. (NCT06714604)
DESCRIPTION:Gemcitabine\, phase 3\, Pancreatic Ductal Adenocarcinoma.\nStud
 y: Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LA
 PC\nEstimated primary completion: 31 December 2032. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/gemcitabine#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06714604
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
